Table 3.
Open in new tab

Clinical Findings at the Time of Torque Teno Virus Assessment Posttransplantation, Stratified According to the Occurrence of Infection in the Subsequent Follow-up Period

CharacteristicsInfectionNo InfectionP Value
(n = 41)(n = 83)
Clinical data
 Infection, n (%)13 (32)4 (5)c<.001
 Allograft rejection,a n (%)9 (22)16 (19).813
 Antiviral treatment, n (%)1 (2)0 (0).331
Laboratory data
 CMV load, copies/mL (IQR)0 (0–140)0 (0–20).082
 Leukocytes, g/L (IQR)6.3 (4.9–8.7)6.6 (4.3–7.8).423
 Neutrophils, g/L (IQR)4.6 (3.8–7.5)2.9 (4.5–6.0).326
 Lymphocytes, g/L (IQR)1.2 (0.7–1.5)1.3 (0.8–1.8).229
 eGFR, mL/min/m2 (IQR)b47 (36–65)50 (34–68).563
 Urinary protein/creatinine ratio, mg/mg (IQR)201 (105–395)192 (98–350).642
 CRP, mg/dL (IQR)0.66 (0.27–2.81)0.27 (0.08–0.70).023
Immunosuppression
 Prednisolone, mg (IQR)5 (5–10)5 (5–11.25).174
 Cyclosporine, n (%)2 (5)6 (7).719
 Tacrolimus, n (%)72 (87)38 (93).384
 Tacrolimus once per day, n (%)11 (28)13 (16).149
 Tacrolimus trough level, ng/mL (IQR)7.3 (5.8–9.7)7.3 (5.6–8.8).524
 Everolimus, n (%)1 (2.4)2 (2.4)>.99
 Belatacept, n (%)1 (2.4)4 (4.8).665
 Mycophenolic acid, n (%)40 (98)80 (98)>.99
 Mycophenolic acid, g (IQR)2 (1–2)1 (1–2).842
CharacteristicsInfectionNo InfectionP Value
(n = 41)(n = 83)
Clinical data
 Infection, n (%)13 (32)4 (5)c<.001
 Allograft rejection,a n (%)9 (22)16 (19).813
 Antiviral treatment, n (%)1 (2)0 (0).331
Laboratory data
 CMV load, copies/mL (IQR)0 (0–140)0 (0–20).082
 Leukocytes, g/L (IQR)6.3 (4.9–8.7)6.6 (4.3–7.8).423
 Neutrophils, g/L (IQR)4.6 (3.8–7.5)2.9 (4.5–6.0).326
 Lymphocytes, g/L (IQR)1.2 (0.7–1.5)1.3 (0.8–1.8).229
 eGFR, mL/min/m2 (IQR)b47 (36–65)50 (34–68).563
 Urinary protein/creatinine ratio, mg/mg (IQR)201 (105–395)192 (98–350).642
 CRP, mg/dL (IQR)0.66 (0.27–2.81)0.27 (0.08–0.70).023
Immunosuppression
 Prednisolone, mg (IQR)5 (5–10)5 (5–11.25).174
 Cyclosporine, n (%)2 (5)6 (7).719
 Tacrolimus, n (%)72 (87)38 (93).384
 Tacrolimus once per day, n (%)11 (28)13 (16).149
 Tacrolimus trough level, ng/mL (IQR)7.3 (5.8–9.7)7.3 (5.6–8.8).524
 Everolimus, n (%)1 (2.4)2 (2.4)>.99
 Belatacept, n (%)1 (2.4)4 (4.8).665
 Mycophenolic acid, n (%)40 (98)80 (98)>.99
 Mycophenolic acid, g (IQR)2 (1–2)1 (1–2).842

Mann-Whitney U test was used for comparing continuous data and group comparisons were made using the Χ2 test. Exact tests were used where applicable.

Abbreviations: CMV, cytomegalovirus; CRP, C reactive protein; eGFR, estimated glomerular filtration rate; IQR, inter quartile range.

aAny episode of biopsy-proven allograft rejection or antirejection therapy preceding torque teno virus assessment.

beGFR was calculated using the Mayo equation [20].

cFour patients had an infection at the time of torque teno virus assessment, but did not develop an infection in the subsequent follow-up period.

Table 3.
Open in new tab

Clinical Findings at the Time of Torque Teno Virus Assessment Posttransplantation, Stratified According to the Occurrence of Infection in the Subsequent Follow-up Period

CharacteristicsInfectionNo InfectionP Value
(n = 41)(n = 83)
Clinical data
 Infection, n (%)13 (32)4 (5)c<.001
 Allograft rejection,a n (%)9 (22)16 (19).813
 Antiviral treatment, n (%)1 (2)0 (0).331
Laboratory data
 CMV load, copies/mL (IQR)0 (0–140)0 (0–20).082
 Leukocytes, g/L (IQR)6.3 (4.9–8.7)6.6 (4.3–7.8).423
 Neutrophils, g/L (IQR)4.6 (3.8–7.5)2.9 (4.5–6.0).326
 Lymphocytes, g/L (IQR)1.2 (0.7–1.5)1.3 (0.8–1.8).229
 eGFR, mL/min/m2 (IQR)b47 (36–65)50 (34–68).563
 Urinary protein/creatinine ratio, mg/mg (IQR)201 (105–395)192 (98–350).642
 CRP, mg/dL (IQR)0.66 (0.27–2.81)0.27 (0.08–0.70).023
Immunosuppression
 Prednisolone, mg (IQR)5 (5–10)5 (5–11.25).174
 Cyclosporine, n (%)2 (5)6 (7).719
 Tacrolimus, n (%)72 (87)38 (93).384
 Tacrolimus once per day, n (%)11 (28)13 (16).149
 Tacrolimus trough level, ng/mL (IQR)7.3 (5.8–9.7)7.3 (5.6–8.8).524
 Everolimus, n (%)1 (2.4)2 (2.4)>.99
 Belatacept, n (%)1 (2.4)4 (4.8).665
 Mycophenolic acid, n (%)40 (98)80 (98)>.99
 Mycophenolic acid, g (IQR)2 (1–2)1 (1–2).842
CharacteristicsInfectionNo InfectionP Value
(n = 41)(n = 83)
Clinical data
 Infection, n (%)13 (32)4 (5)c<.001
 Allograft rejection,a n (%)9 (22)16 (19).813
 Antiviral treatment, n (%)1 (2)0 (0).331
Laboratory data
 CMV load, copies/mL (IQR)0 (0–140)0 (0–20).082
 Leukocytes, g/L (IQR)6.3 (4.9–8.7)6.6 (4.3–7.8).423
 Neutrophils, g/L (IQR)4.6 (3.8–7.5)2.9 (4.5–6.0).326
 Lymphocytes, g/L (IQR)1.2 (0.7–1.5)1.3 (0.8–1.8).229
 eGFR, mL/min/m2 (IQR)b47 (36–65)50 (34–68).563
 Urinary protein/creatinine ratio, mg/mg (IQR)201 (105–395)192 (98–350).642
 CRP, mg/dL (IQR)0.66 (0.27–2.81)0.27 (0.08–0.70).023
Immunosuppression
 Prednisolone, mg (IQR)5 (5–10)5 (5–11.25).174
 Cyclosporine, n (%)2 (5)6 (7).719
 Tacrolimus, n (%)72 (87)38 (93).384
 Tacrolimus once per day, n (%)11 (28)13 (16).149
 Tacrolimus trough level, ng/mL (IQR)7.3 (5.8–9.7)7.3 (5.6–8.8).524
 Everolimus, n (%)1 (2.4)2 (2.4)>.99
 Belatacept, n (%)1 (2.4)4 (4.8).665
 Mycophenolic acid, n (%)40 (98)80 (98)>.99
 Mycophenolic acid, g (IQR)2 (1–2)1 (1–2).842

Mann-Whitney U test was used for comparing continuous data and group comparisons were made using the Χ2 test. Exact tests were used where applicable.

Abbreviations: CMV, cytomegalovirus; CRP, C reactive protein; eGFR, estimated glomerular filtration rate; IQR, inter quartile range.

aAny episode of biopsy-proven allograft rejection or antirejection therapy preceding torque teno virus assessment.

beGFR was calculated using the Mayo equation [20].

cFour patients had an infection at the time of torque teno virus assessment, but did not develop an infection in the subsequent follow-up period.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close